Biocon Biologics’ Insugen formulations will be available to patients at all Department of Health hospitals, district health departments and health clinics
Biocon Biologics’ Insugen formulations will be available to patients at all Department of Health hospitals, district health departments and health clinics
Biocon Biologics Limited (BBL), a subsidiary of Biocon, announced on Tuesday that it has been awarded a three-year contract worth US$90 million by the Malaysian government to supply Insugen brand of recombinant human insulin.
Biocon Sdn Bhd., a subsidiary of Biocon Biologics, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a pharmaceutical and biotechnology company in Malaysia.
According to an official statement, Biocon Biologics’ Insugen formulations will be available to patients at all Department of Health hospitals, district health departments and health clinics.
“This new government contract will allow us to bring recombinant human insulin to over 4,00,000 people with diabetes and support the government on its journey to equal access to diabetes care,” said Susheel Umesh, Chief Commercial Officer, Emerging Markets, Biocon Biologics .
The rh insulin formulations Insugen-R, Insugen-N and Insugen-30/70 are manufactured by Biocon Sdn. Bhd. in Johor and have been approved by the National Pharmaceutical Regulatory Authority (NPRA) in Malaysia, the press release said.
Biocon Biologics has administered over 2.75 billion doses of rh insulin to patients around the world.
